drugset / Trial / NCT01602562

Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients

NCT01602562

Phase 3 Completed 40 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the preventive efficacy for HSV infection and safety of valaciclovir (VACV) in the adult and pediatric HSCT patients.

Timeline

Start
2012-05-07
Primary completion
2013-05-01
Completion
2013-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Valaciclovir Unknown 25 mg/kg Oral
Subject Valaciclovir Unknown 500 mg Oral